Patents Examined by Raymond Henley, III
  • Use of prostaglandins F2Alpha and analogues for the healing of corneal and conjunctival lesions
    Patent number: 9072750
    Abstract: The invention relates to a composition for use in treating corneal and conjunctival lesions, wherein the composition comprises a prostaglandin F2alpha or analogue, in a therapeutic amount, said composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative; the invention also relates to a method for treating surface ocular conditions in a patient in need thereof, comprising administering a composition of the invention.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: July 7, 2015
    Assignee: SANTEN SAS
    Inventors: Jean-Sébastien Garrigue, Frédéric Lallemand, Philippe Daull, Christophe Baudouin
  • Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
    Patent number: 9066920
    Abstract: This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: June 30, 2015
    Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Ben Whalley, Gary Stephens, Claire Williams, Geoffrey Guy, Stephen Wright, Tetsuro Kikuchi
  • Dry powder inhaler
    Patent number: 9066957
    Abstract: This invention provides a dry powder inhaler comprising: a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of salmeterol per actuation is less than 50 ?g; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose. A method of treating a patient includes administering to a patient a dry powder medicament having fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of salmeterol per actuation is less than 50 ?g; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: June 30, 2015
    Assignee: TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC.
    Inventors: Mukul Dalvi, Seah Kee Tee
  • Intravascular delivery of nanoparticle compositions and uses thereof
    Patent number: 9061014
    Abstract: The present invention provides methods of delivering a composition comprising nanoparticles that comprise a macrolide and an albumin by directly injecting the nanoparticle composition into the blood vessel wall or the tissue surrounding the blood vessel wall. The methods can be used for inhibiting negative remodeling or vascular fibrosis in the blood vessel and are useful for treating various diseases.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: June 23, 2015
    Assignees: ABRAXIS BIOSCIENCE, LLC, MERCATOR MEDSYSTEMS, INC.
    Inventors: Kirk Seward, Neil P. Desai
  • Bendamustine pharmaceutical compositions
    Patent number: 9061011
    Abstract: Provided herein are pharmaceutical formulations of dry-powder bendamustine suitable for pharmaceutical use. Also provided are methods of producing dry-powder bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: June 23, 2015
    Inventor: Vasilios Voudouris
  • Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
    Patent number: 9061029
    Abstract: The present invention relates to a regimen for the administration of a pyrimidylaminobenzamide of formula I wherein the radicals as defined herein, or of a pharmaceutically acceptable salt thereof, for the treatment of proliferative disorders, particularly solid and liquid tumors, and other pathological conditions mediated by the Bcr-Abl oncoprotein, the cell transmembrane tyrosine kinase receptor c-Kit, DDR1 (discoidin domain receptor 1), DDR2 (discoidin domain receptor 2) or PDGF-R (platelet derived growth factor receptor) kinase activity, wherein the pyrimidylaminobenzamide of formula I and, optionally, pharmaceutically acceptable carriers, are dispersed in a fruit preparation.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: June 23, 2015
    Assignee: Novartis AG
    Inventors: Neil Gallagher, Ophelia Yin
  • Methods for treating or preventing cancer and neurodegenerative diseases
    Patent number: 9056857
    Abstract: Provided are methods of treating or preventing a neurodegenerative disease comprising administering to a subject having a neurodegenerative disease an effective amount of a compound of Formula I: where X, R1, R2, subscript m, subscript n and subscript v are as defined herein.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: June 16, 2015
    Assignee: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Lei Zhu, Yueming Li
  • Pharmaceutical compositions comprising DGLA, 15-HEPE, and/or 15-HETrE and methods of use thereof
    Patent number: 9056086
    Abstract: The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used singly or in combination with anti-bacterial agents for the treatment of disease and/or disorders such as acne or atopic dermatitis.
    Type: Grant
    Filed: September 18, 2012
    Date of Patent: June 16, 2015
    Assignee: Dignity Sciences Limited
    Inventors: Mehar Manku, John Climax, David Coughlan
  • 4-hydroxybutyric acid analogs
    Patent number: 9051261
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: June 9, 2015
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung
  • Vitamin C and vitamin K, and compositions thereof for treatment of osteolysis or prolongation of prosthetic implant
    Patent number: 9050265
    Abstract: Provided herein is a method of treating, preventing, or managing osteolysis in a subject, comprising administering to the subject a therapeutically effective amount of vitamin C, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, in combination with vitamin K, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
    Type: Grant
    Filed: July 19, 2010
    Date of Patent: June 9, 2015
    Assignee: Summa Health System
    Inventors: James M. Jamison, Thomas M. Miller, Deborah R. Neal, Mark Willam Kovacik, Michael John Askew, Richard Albert Mostardi
  • Beneficial effects of combination therapy on cholesterol
    Patent number: 9050342
    Abstract: The present invention discloses pharmaceutical combination therapies for the treatment or prevention of diseases in a mammal comprising a Janus Kinase inhibitor or a pharmaceutically acceptable salt thereof and a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions containing the same and kits for achieving a therapeutic effect in a mammal comprising pharmaceutical combination therapies are further described.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: June 9, 2015
    Assignee: Pfizer Inc.
    Inventors: Keith Stuart Kanik, Samuel H. Zwillich, Mary Gardiner Boy
  • Small molecule inhibitors of polynucleotide kinase/phosphatase, poly(ADP-ribose) polymerase and uses thereof
    Patent number: 9040551
    Abstract: The present invention generally relates to use of compounds and compositions as a chemosensitizers and/or radiosensitizers and/or inhibitors of PNKP phosphatase activity. The present invention provides pharmaceutical combinations and/or a pharmaceutically acceptable salt thereof, kits containing such compounds and/composition and methods of using such compounds and/or compositions.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: May 26, 2015
    Assignees: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA, ALBERTA HEALTH SERVICES
    Inventors: Michael Weinfeld, Dennis G. Hall, Feridoun Karimi-Busheri, Gary Kenneth Freschauf, Todd Randall Mereniuk
  • Methods and compositions for modulating tau levels
    Patent number: 9040521
    Abstract: Methods and agents for reducing a level of an acetylated Tau polypeptide in a cell are provided. Methods for treating a tauopathy in an individual are also provided. Also provided is a method for diagnosing a cognitive impairment disorder in an individual. Methods for identifying an agent suitable for treating a tauopathy are also provided.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: May 26, 2015
    Assignee: THE J. DAVID GLADSTONE INSTITUTES
    Inventor: Li Gan
  • Boron-containing small molecules as anti-inflammatory agents
    Patent number: 9029353
    Abstract: Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: May 12, 2015
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Stephen J. Baker, Virginia Sanders, Tsutomu Akama, Carolyn Bellinger-Kawahara, Yvonne Freund, Kirk R. Maples, Jacob J. Plattner, Yong-Kang Zhang, Huchen Zhou, Vincent S. Hernandez
  • Choline salt of an anti-inflammatory substituted cyclobutenedione compound
    Patent number: 9018261
    Abstract: 6-chloro-3-[2-(1-ethyl-propylamino)-3,4-dioxo-cyclobut-1-enylamino]-2-hydroxy-N-methoxy-N-methyl-benzenesulfonamide choline, solid pharmaceutical compositions and oral dosage forms that contain said compound, and a method of using such compositions and oral dosage forms to treat people who have inflammatory, obstructive or allergic conditions and diseases are disclosed.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: April 28, 2015
    Assignee: Novartis AG
    Inventors: Ameet Vijay Ambarkhane, Arnaud Mauler, Carsten Timpe, Urs Baettig
  • Development of a new formulation overcoming thymus atrophy with concomitantly enhancement of anti-inflammatory effect of dexamethasone
    Patent number: 9018196
    Abstract: This invention provides a method of preventing and/or treating thymus degeneration comprising administering an effective amount of dihydromyricetin to a subject in need thereof, in which the degeneration is induced by dexamethasone. In one embodiment, the thymus degeneration is induced during the course of treatment of inflammation by dexamethasone.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: April 28, 2015
    Assignee: Macau University of Science and Technology
    Inventors: Liang Liu, Ting Li, Fenggen Yan
  • Sexual dysfunction
    Patent number: 9012454
    Abstract: This document provides methods and materials related to treating mammals (e.g., humans) having a sexual dysfunction that is refractory to treatment with a PDE V inhibitor. For example, methods and materials related to the use of an ACE inhibitor and/or an angiotensin II receptor blocker with a PDE V inhibitor to treat mammals having a sexual dysfunction (e.g., erective dysfunction) that is unresponsive to treatment with a PDE V inhibitor are provided.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: April 21, 2015
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Frank V. Brozovich
  • Type A gelatin capsule containing PUFA in free acid form
    Patent number: 9012501
    Abstract: A pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterized in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of the present invention over a soft to gelatin capsule containing the same formulation but comprising gelatin extracted by an extraction process comprising alkali pre-treatment of the collagen source is that the present invention does not harden significantly over time and thus has a longer shelf life.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: April 21, 2015
    Assignee: Chrysalis Pharma AG
    Inventors: Jean-Pierre Sachetto, Roly Bufton, Thomas Buser
  • Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
    Patent number: 9012432
    Abstract: A combination therapy for treating osteoarthritis is disclosed. The combination therapy includes the co-administration of a steroid and Zoledronic Acid. The coadministration of a steroid decreases the production of cytokines, and, therefore, decreases the pro-inflammatory effects of Zoledronic Acid. The co-administration of Zoledronic Acid with steroids treats osteoarthritis, and helps to prevent the onset of osteoarthritis in patients at risk for osteoarthritis.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: April 21, 2015
    Assignee: Levolta Pharmaceuticals, Inc.
    Inventor: Ketan Desai
  • PKC-? activator
    Patent number: 9012500
    Abstract: The present invention aims to obtain an optical isomer of DCP-LA, which shows more superior activity and is suitable for clinical utilization, and provide an agent having a superior PKC-? activation action, a prophylactic and/or therapeutic agent for neurotransmitter release disorders, and a prophylactic and/or therapeutic agent for neuropsychiatric diseases, which contain the isomer as an active ingredient. A compound represented by the following formula: or a pharmaceutically acceptable salt thereof, and a selective PKC-? activator containing same as an active ingredient, and is the like.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: April 21, 2015
    Assignee: Nishizaki Bioinformation Research Institute
    Inventors: Tomoyuki Nishizaki, Akito Tanaka